Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema

StreetInsider01-10

AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils, macrophages, and ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Alicent
01-17
Alicent
文章顶部列出的两个股票代码和这家公司毫无关系

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2402156309?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2024-01-10 01:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2402156309","market":"us","top_or_hot":-1,"title":"Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema","media":"StreetInsider","content":"<div>\n<p>AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils, macrophages, and ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=22613022\">网页链接</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-10 01:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=22613022><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils, macrophages, and ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=22613022\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1951200564.SGD","symbol_name":"Natixis Thematics AI & Robotics Fund R/A SGD","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=22613022","article_id":"2402156309","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2402156309","pubTimestamp":1704820140,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"Aviceda is advancing the development of AVD-104, a Novel Glyco-Mimetic Nanoparticle, for the treatment of Diabetic Macular Edema as an indication expansion in addition to Geographic Atrophy ; AVD-104 is currently enrolling patients with GA in the SIGLEC Phase 2/3 Trial.A multi-center, multi-dose, open-label safety and tolerability study will enroll 30 patients to evaluate a low and high dose of AVD-104, with topline results expected in Q2 2024.Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today that they have enrolled the first patient in the GLYCO Phase 2 U.S. clinical trial evaluating their lead ophthalmic candidate AVD-104 for the management of diabetic macular edema . AVD-104 is an engineered glycan  nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated ret","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","BK4566":"资本集团","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","BK4575":"芯片概念","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","BK4588":"碎股","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK4141":"半导体产品","AVD":"美国先锋","LU0082616367.USD":"摩根大通美国科技A（dist）","LU0056508442.USD":"贝莱德世界科技基金A2","AMD":"美国超微公司","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","BK4573":"虚拟现实","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4512":"苹果概念","BK4093":"化肥与农用药剂","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK4529":"IDC概念","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4585":"ETF&股票定投概念","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","BK4534":"瑞士信贷持仓"},"translate_title":"Aviceda宣布第一名患者参加2期GLYCO临床试验，评估AVD-104治疗糖尿病性黄斑水肿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVD":1,"AMD":1},"content_text":"AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils, macrophages, and microglia, and repolarizing them to their resolution state.\n\nAviceda is advancing the development of AVD-104, a Novel Glyco-Mimetic Nanoparticle, for the treatment of Diabetic Macular Edema as an indication expansion in addition to Geographic Atrophy (lead indication); AVD-104 is currently enrolling patients with GA in the SIGLEC Phase 2/3 Trial.\n\nA multi-center, multi-dose, open-label safety and tolerability study will enroll 30 patients to evaluate a low and high dose of AVD-104, with topline results expected in Q2 2024.\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today that they have enrolled the first patient in the GLYCO Phase 2 U.S. clinical trial evaluating their lead ophthalmic candidate AVD-104 for the management of diabetic macular edema (DME). AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils, macrophages, and microglia, and repolarizing them to their resolution state.\n\nAshkan Abbey, M.D., of Texas Retina Associates said, “I am honored to dose AVD-104 in the first patient in the GLYCO trial to evaluate its potentially next-generation dual mechanism of action to reduce the chronic inflammation that drives many cases of DME.”\n\nMohamed Genead, M.D., Aviceda’s Co-founder and CEO said, “We are excited to evaluate the ability of AVD-104’s unique mechanism of action to provide DME patients with a safe treatment that may improve outcomes in eyes with DME driven by inflammatory and VEGF-mediated mechanisms.”\n\n“AVD-104 down-regulates neutrophils and has been shown to reduce the release of inflammatory cytokines,” explained David Callanan, M.D., Aviceda’s Chief Medical Officer and Senior Vice President. “There is still a need for improvement in the treatment of DME and we believe it may offer therapeutic advantages in the management of DME, and potentially in diabetic ischemia.”\n\nThe GLYCO Phase 2 U.S. clinical trial will evaluate the safety and treatment effects of intravitreal AVD-104 in patients with DME. This multi-center, open-label safety and tolerability study will enroll 30 patients to evaluate a low and high dose of AVD-104 with 3-month follow-up. The primary endpoint will be the incidence and severity of ocular and systemic adverse events. Secondary endpoint analyses will include standard evaluations of treatment efficacy, including macular thickness and vision. Further exploratory variables will include the potential effect of AVD-104 on macular ischemia.\n\nFurther information regarding the GLYCO trial can be found HERE.\n\nAbout Aviceda Therapeutics and AVD-104\n\nAviceda is a private, late-stage clinical biotechnology company located in Cambridge, MA, with a proprietary HALOS™ nanotechnology platform and a clinical stage ophthalmic candidate, AVD-104, for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD) and diabetic macular edema. AVD-104 is a promising intravitreal glycan-coated nanoparticle with a dual mechanism of action that modulates critical inflammatory cellular and complement pathways through 1) direct inhibition of the activity of damaging neutrophils and phagocytic macrophages and repolarization of activated macrophages to their resolution state and 2) inhibition of complement cascade amplification. AVD-104 has completed dosing in the single ascending dose Part I of the company’s Phase 2/3 SIGLEC trial, which is evaluating patients with geographic atrophy secondary to AMD. Topline three-month data from Part I is expected in early 2024 along with the initiation of Part II, which is a double-masked, randomized, active comparator trial. Part II of the Phase 2/3 trial will enroll 300 patients across U.S. clinical sites.\n\nAlong with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including oncology, immunology, neurology, and fibrosis.\n\nLearn more about Aviceda Therapeutics.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240109176126/en/\n\nOrganization Contact:\nAviceda Therapeutics Inc.\n[email protected]\n\nSource: Aviceda Therapeutics","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":263861218226416,"gmtCreate":1705454887797,"gmtModify":1705454889365,"author":{"id":"3547492843908436","authorId":"3547492843908436","authorIdStr":"3547492843908436","name":"Alicent","avatar":"https://static.tigerbbs.com/0a7b09bfad47e4ab0b7a96cdfaec4d6d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"文章顶部列出的两个股票代码和这家公司毫无关系","listText":"文章顶部列出的两个股票代码和这家公司毫无关系","text":"文章顶部列出的两个股票代码和这家公司毫无关系","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/263861218226416","repostId":2402156309,"repostType":2,"repost":{"id":"2402156309","pubTimestamp":1704820140,"share":"https://www.laohu8.com/m/news/2402156309?lang=&edition=full","pubTime":"2024-01-10 01:09","market":"us","language":"en","title":"Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema","url":"https://stock-news.laohu8.com/highlight/detail?id=2402156309","media":"StreetInsider","summary":"Aviceda is advancing the development of AVD-104, a Novel Glyco-Mimetic Nanoparticle, for the treatment of Diabetic Macular Edema as an indication expansion in addition to Geographic Atrophy ; AVD-104 is currently enrolling patients with GA in the SIGLEC Phase 2/3 Trial.A multi-center, multi-dose, open-label safety and tolerability study will enroll 30 patients to evaluate a low and high dose of AVD-104, with topline results expected in Q2 2024.Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today that they have enrolled the first patient in the GLYCO Phase 2 U.S. clinical trial evaluating their lead ophthalmic candidate AVD-104 for the management of diabetic macular edema . AVD-104 is an engineered glycan  nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated ret","content":"<html><body><div>\n<p>\n<i>AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils, macrophages, and microglia, and repolarizing them to their resolution state.</i>\n</p><p>\n<i>Aviceda is advancing the development of AVD-104, a Novel Glyco-Mimetic Nanoparticle, for the treatment of Diabetic Macular Edema as an indication expansion in addition to Geographic Atrophy (lead indication); AVD-104 is currently enrolling patients with GA </i><i>in the SIGLEC Phase 2/3 Trial.</i>\n</p><p>\n<i>A multi-center, multi-dose, open-label safety and tolerability study will enroll 30 patients to evaluate a low and high dose of AVD-104, with topline results expected in Q2 2024.</i>\n</p>\n<p> CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today that they have enrolled the first patient in the GLYCO Phase 2 U.S. clinical trial evaluating their lead ophthalmic candidate AVD-104 for the management of diabetic macular edema (DME). AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils, macrophages, and microglia, and repolarizing them to their resolution state.\n</p><p>\n<b>Ashkan Abbey, M.D.,</b> of Texas Retina Associates said, “I am honored to dose AVD-104 in the first patient in the GLYCO trial to evaluate its potentially next-generation dual mechanism of action to reduce the chronic inflammation that drives many cases of DME.”\n</p><p>\n<b>Mohamed Genead, M.D.,</b> Aviceda’s Co-founder and CEO said, “We are excited to evaluate the ability of AVD-104’s unique mechanism of action to provide DME patients with a safe treatment that may improve outcomes in eyes with DME driven by inflammatory and VEGF-mediated mechanisms.”\n</p><p>\n“AVD-104 down-regulates neutrophils and has been shown to reduce the release of inflammatory cytokines,” explained <b>David Callanan, M.D.</b><b>,</b> Aviceda’s Chief Medical Officer and Senior Vice President. “There is still a need for improvement in the treatment of DME and we believe it may offer therapeutic advantages in the management of DME, and potentially in diabetic ischemia.”\n</p><p>\nThe GLYCO Phase 2 U.S. clinical trial will evaluate the safety and treatment effects of intravitreal AVD-104 in patients with DME. This multi-center, open-label safety and tolerability study will enroll 30 patients to evaluate a low and high dose of AVD-104 with 3-month follow-up. The primary endpoint will be the incidence and severity of ocular and systemic adverse events. Secondary endpoint analyses will include standard evaluations of treatment efficacy, including macular thickness and vision. Further exploratory variables will include the potential effect of AVD-104 on macular ischemia.\n</p><p>\nFurther information regarding the GLYCO trial can be found <b>HERE</b>.\n</p><div><div><div></div></div></div><p>\n<b>About Aviceda Therapeutics and AVD-104</b>\n</p><p>\nAviceda is a private, late-stage clinical biotechnology company located in Cambridge, MA, with a proprietary HALOS™ nanotechnology platform and a clinical stage ophthalmic candidate, AVD-104, for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD) and diabetic macular edema. AVD-104 is a promising intravitreal glycan-coated nanoparticle with a dual mechanism of action that modulates critical inflammatory cellular and complement pathways through 1) direct inhibition of the activity of damaging neutrophils and phagocytic macrophages and repolarization of activated macrophages to their resolution state and 2) inhibition of complement cascade amplification. AVD-104 has completed dosing in the single ascending dose Part I of the company’s Phase 2/3 SIGLEC trial, which is evaluating patients with geographic atrophy secondary to AMD. Topline three-month data from Part I is expected in early 2024 along with the initiation of Part II, which is a double-masked, randomized, active comparator trial. Part II of the Phase 2/3 trial will enroll 300 patients across U.S. clinical sites.\n</p><p>\nAlong with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including oncology, immunology, neurology, and fibrosis.\n</p><p>\nLearn more about Aviceda Therapeutics.\n</p><p><img src=\"https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20240109176126r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\"/><span></span></p><p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20240109176126/en/</span></p>\n<p>\n<b>Organization Contact:\n</b>Aviceda Therapeutics Inc.\n<span>[email protected]</span>\n</p>\n<p>Source: Aviceda Therapeutics</p> </div></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-10 01:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=22613022><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils, macrophages, and ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=22613022\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0082616367.USD":"摩根大通美国科技A（dist）","LU0056508442.USD":"贝莱德世界科技基金A2","BK4573":"虚拟现实","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","BK4512":"苹果概念","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4093":"化肥与农用药剂","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4529":"IDC概念","AMD":"美国超微公司","BK4141":"半导体产品","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK4554":"元宇宙及AR概念","BK4532":"文艺复兴科技持仓","BK4575":"芯片概念","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","BK4566":"资本集团","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","BK4588":"碎股","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","AVD":"美国先锋","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC"},"source_url":"https://www.streetinsider.com/dr/news.php?id=22613022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2402156309","content_text":"AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils, macrophages, and microglia, and repolarizing them to their resolution state.\n\nAviceda is advancing the development of AVD-104, a Novel Glyco-Mimetic Nanoparticle, for the treatment of Diabetic Macular Edema as an indication expansion in addition to Geographic Atrophy (lead indication); AVD-104 is currently enrolling patients with GA in the SIGLEC Phase 2/3 Trial.\n\nA multi-center, multi-dose, open-label safety and tolerability study will enroll 30 patients to evaluate a low and high dose of AVD-104, with topline results expected in Q2 2024.\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic, non-resolving inflammation, announced today that they have enrolled the first patient in the GLYCO Phase 2 U.S. clinical trial evaluating their lead ophthalmic candidate AVD-104 for the management of diabetic macular edema (DME). AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammation by targeting the self-pattern recognition receptors on overly activated retinal neutrophils, macrophages, and microglia, and repolarizing them to their resolution state.\n\nAshkan Abbey, M.D., of Texas Retina Associates said, “I am honored to dose AVD-104 in the first patient in the GLYCO trial to evaluate its potentially next-generation dual mechanism of action to reduce the chronic inflammation that drives many cases of DME.”\n\nMohamed Genead, M.D., Aviceda’s Co-founder and CEO said, “We are excited to evaluate the ability of AVD-104’s unique mechanism of action to provide DME patients with a safe treatment that may improve outcomes in eyes with DME driven by inflammatory and VEGF-mediated mechanisms.”\n\n“AVD-104 down-regulates neutrophils and has been shown to reduce the release of inflammatory cytokines,” explained David Callanan, M.D., Aviceda’s Chief Medical Officer and Senior Vice President. “There is still a need for improvement in the treatment of DME and we believe it may offer therapeutic advantages in the management of DME, and potentially in diabetic ischemia.”\n\nThe GLYCO Phase 2 U.S. clinical trial will evaluate the safety and treatment effects of intravitreal AVD-104 in patients with DME. This multi-center, open-label safety and tolerability study will enroll 30 patients to evaluate a low and high dose of AVD-104 with 3-month follow-up. The primary endpoint will be the incidence and severity of ocular and systemic adverse events. Secondary endpoint analyses will include standard evaluations of treatment efficacy, including macular thickness and vision. Further exploratory variables will include the potential effect of AVD-104 on macular ischemia.\n\nFurther information regarding the GLYCO trial can be found HERE.\n\nAbout Aviceda Therapeutics and AVD-104\n\nAviceda is a private, late-stage clinical biotechnology company located in Cambridge, MA, with a proprietary HALOS™ nanotechnology platform and a clinical stage ophthalmic candidate, AVD-104, for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD) and diabetic macular edema. AVD-104 is a promising intravitreal glycan-coated nanoparticle with a dual mechanism of action that modulates critical inflammatory cellular and complement pathways through 1) direct inhibition of the activity of damaging neutrophils and phagocytic macrophages and repolarization of activated macrophages to their resolution state and 2) inhibition of complement cascade amplification. AVD-104 has completed dosing in the single ascending dose Part I of the company’s Phase 2/3 SIGLEC trial, which is evaluating patients with geographic atrophy secondary to AMD. Topline three-month data from Part I is expected in early 2024 along with the initiation of Part II, which is a double-masked, randomized, active comparator trial. Part II of the Phase 2/3 trial will enroll 300 patients across U.S. clinical sites.\n\nAlong with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including oncology, immunology, neurology, and fibrosis.\n\nLearn more about Aviceda Therapeutics.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240109176126/en/\n\nOrganization Contact:\nAviceda Therapeutics Inc.\n[email protected]\n\nSource: Aviceda Therapeutics","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2402156309"}